Medicus Sciences Acquisition Corp. announced today the closing of its initial public offering of 9,200,000 units, which included the full exercise of the underwriter's over-allotment option to purchase 1,200,000 units, at a price to the public of $10.00 per unit, for aggregate gross proceeds of $92,000,000. The units commenced trading on the Nasdaq Capital Market ("Nasdaq") on February 16, 2021 under the symbol "MSACU." Each unit consists of (i) one Class A ordinary share, (ii) one-ninth of one redeemable warrant, and (iii) a contingent right to receive, in certain circumstances, at least two-ninths of one redeemable warrant following the initial business combination. Once the securities comprising the units begin trading separately, the Class A ordinary shares and warrants are expected to be traded on the Nasdaq under the symbols "MSAC" and "MSACW," respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade.

Maxim Group LLC acted as sole book-running manager for the offering.

About Medicus Sciences Acquisition Corp.

MSAC is a blank check company incorporated as a Cayman Islands exempted company and incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. While MSAC may acquire a company in any industry, it expects that its focus will be on the healthcare industry, particularly the medical technology sector, both in the United States and internationally. MSAC's sponsor, Medicus Sciences Holdings LLC, is an affiliate of Altium Capital Management, LP ("Altium") and Sio Capital Management, LLC ("Sio"), two healthcare-focused investment funds with combined gross investment assets of over $1.0 billion.